

Special Issue

Novel Evidence Generating Tools for Precision Oncology

Message from the Guest Editors

The molecular dissection of cancer subtypes imposes a “new methodology” for assessing the safety and efficacy of novel drugs in specific cancer subtypes. In recent years, different approaches have been used to face this need, with diverse results. Moreover, the possibility to use data coming from the real world for regulatory and developmental purposes can open completely new scenarios. The purpose of this issue is to encourage discussion around and improve the visibility of all these points. We look forward to receiving your contributions.

Guest Editors

Dr. Gennaro Daniele

Phase 1 Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS,
00168 Rome, Italy

Dr. Rosa Falcone

Medical Oncology, Policlinico Universitario Agostino Gemelli, UOC Fase
1 Largo Gemelli 8, 00168 Rome, Italy

Deadline for manuscript submissions

closed (1 July 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/85876

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)